Catalog No.
RVV13802
Species reactivity
Vaccinia virus
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Envelope protein H3, Ag35, Virion envelope protein p35, H3L, Vaccinia
Concentration
2.89 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20497, Q0NPX5, Q80DY1
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
PBS, pH 7.4 with 0.2M Arg
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
B9
Note
For research use only.
The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant protein., PMID:9930187
A capripoxvirus detection PCR and antibody ELISA based on the major antigen P32, the homolog of the vaccinia virus H3L gene., PMID:10485266
Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo., PMID:10708453
Characterization of vaccinia virus intracellular cores: implications for viral uncoating and core structure., PMID:10729126
Characterization of the vaccinia virus H3L envelope protein: topology and posttranslational membrane insertion via the C-terminal hydrophobic tail., PMID:10906204
Identification and characterization of three immunodominant structural proteins of fowlpox virus., PMID:12208962
Heparin binding activity of orf virus F1L protein., PMID:15351483
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice., PMID:16140750
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine., PMID:18234801
An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling., PMID:18480455
Attenuation of vaccinia virus by the expression of human Flt3 ligand., PMID:20504356
Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model., PMID:20587859
Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs., PMID:22100890
Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies., PMID:23133652
Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models., PMID:26723250
Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models., PMID:28259752
Phage display antibodies against ectromelia virus that neutralize variola virus: Selection and implementation for p35 neutralizing epitope mapping., PMID:29427674
Molecular Modelling and Insilico Engineering of PapMV-CP Towards Display and Development of Capripox Viral Like Particles Based on Immunogenic P32 Envelop Protein is the Homologous of the Vaccinia-Viral H3L Gene: An Insilico Approach., PMID:32421016
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses., PMID:33675226
New p35 (H3L) Epitope Involved in Vaccinia Virus Neutralization and Its Deimmunization., PMID:35746695
Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens., PMID:36687315
Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity., PMID:37300753
Expression of F1L, a vaccinia virus H3L transmembrane protein analogue of orf virus, and its successful purification as a diagnostic antigen., PMID:39136814
Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus., PMID:39321566
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
For research use only. Not for human or drug use.
